PTPN2 and cancer: PVD-06 was shown to induce significant TCPTP degradation in various cell lines, in a dose-dependent manner and, consequently, promoted T cell proliferation, amplified IFNγ signaling and inhibited melanoma B16F10 cell growth, thus exhibiting a potential for cancer immunotherapy [106].